Compare iShares MSCI South Korea ETF (EWY) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Novo Nordisk A/S — how do they compare? iShares MSCI South Korea ETF trades at $175.93, while Novo Nordisk A/S trades at $46.39 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while iShares MSCI South Korea ETF pays none, and iShares MSCI South Korea ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| EWY | NVO | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $63.98 |
52-Week Low | $71.22 | $35.29 |
Market Cap | — | $207.85B |
Enterprise Value | — | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY, the iShares MSCI South Korea ETF, trades at $175.87, up 7.82% in 24 hours, with a neutral technical signal overall. Recent news highlights volatility in South Korean equities tied to AI and semiconductor stocks, including government support initiatives and foreign capital outflows. The ETF's technical indicators show mixed signals, with bullish moving averages but neutral oscillators, while support and resistance levels suggest near-term consolidation.
The outlook for EWY hinges on South Korea's semiconductor sector recovery and broader market sentiment. Opportunities include potential rebounds from oversold conditions and government-backed chip investments, but risks involve continued volatility from AI trade unwinds and global macroeconomic pressures. Investor caution is warranted amid mixed analyst views and regulatory scrutiny on leveraged ETFs.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
